VNRX-5133-103: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics of VNRX-5133 in Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs VNRX 5133 (Primary) ; VNRX-5022 (Primary)
- Indications Bacteroides infections
- Focus Pharmacokinetics
- Sponsors VenatoRx Pharmaceuticals
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2017 New trial record